Psychedelic Drugs Market will worth USD 6703.3 million by 2030 : GreyViews
January 13, 2023 13:00 ET
|
GreyViews
Pune India, Jan. 13, 2023 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle...
Psychedelic Drugs Market Reaches US$6330.0 Mn by 2026 from US$3210.0 Mn in 2021, at a Healthy Pace of 14.5% CAGR: Fairfield Market Research
July 07, 2022 08:47 ET
|
Fairfield Consultancy Services OPC Pvt Ltd
London, July 07, 2022 (GLOBE NEWSWIRE) -- The demand for psychedelic drugs has shot up in recent years as the awareness about mental health issues reaches all classes, irrespective of age and...
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study
July 07, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian...
Psychedelic Drugs Market CAGR at +13.3% with Analysis of Growing Technology Trends, Industry Research, Future Growth and Size, Projection by 2028
July 14, 2021 16:55 ET
|
Data Bridge Market Research
SAN FRANCISCO, July 14, 2021 (GLOBE NEWSWIRE) -- Psychedelic Drugs Market Research Report gives insightful analysis of the market along with its comprehensive understanding and its commercial...
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
June 17, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all...
XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies
June 15, 2021 11:10 ET
|
XPhyto Therapeutics Corp.
VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on...
Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF
March 29, 2021 07:02 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke
March 17, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage...
Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference
February 25, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...